IMIDomics
IMIDomics is a biotechnology company developing first-in-class therapeutics for immune-mediated inflammatory diseases using a proprietary Clinical Discovery Engine built on 17+ years of multi-omics patient data and an ISO-certified biobank of over 17,000 IMID patients, monetizing through licensing and research collaborations with pharmaceutical partners.
- Company typePrivate
- Founded2015
- HeadquartersBarcelona, Spain
- Headcount11–50
- GTM typeB2B
- OfferingServices
What IMIDomics does
IMIDomics is a clinical-stage biotechnology company founded in 2015 as a spin-off from the Vall d'Hebron University Hospital and the IMID Consortium initiated by Dr. Sara Marsal in 2006. The company is focused on discovering and developing first-in-class therapeutics for immune-mediated inflammatory diseases (IMIDs), targeting eight indications: Systemic Lupus Erythematosus, Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Atopic Dermatitis, and Sjögren's Syndrome. Its core asset is a proprietary Clinical Discovery Engine (also referred to as the Precision Discovery Platform) that combines 17+ years of patient data from a network of 130+ recruiting centers and 300+ investigators across Spain (with extension to Paraguay), an ISO-certified IMID-Biobank with >17,000 patient samples and >1M biological specimens, >10,000 clinical variables, and 2M+ data points, processed through multi-omics analyses and bioinformatics to identify novel drug targets and biomarkers for patient stratification. The lead pipeline asset, IMB1001, is a first-in-class anti-CD226 antibody modulating innate and adaptive immunity.
The company monetizes through a licensing and partnership model rather than direct commercialization. Revenue streams consist of research collaborations and professional services engagements with pharmaceutical partners, supplemented by potential milestone payments and royalties from out-licensed drug candidates. Strategic partners and investors include Bristol Myers Squibb, Evotec SE, UCB (which made a strategic equity investment in March 2024 and completed a full acquisition in June 2026), WuXi Biologics, Twist Bioscience, Formation Bio (which licensed the anti-CD226 program in July 2025), and TNAX Biopharma (original IMB1001 licensor). Go-to-market is enterprise-oriented, targeting large pharmaceutical companies for co-development, licensing, and commercialization of IMID therapeutics, with academic medical centers serving as secondary collaborators. As of June 2026, IMIDomics operates as a subsidiary of UCB following acquisition, with headquarters in San Rafael, California and a permanent European establishment in Barcelona, Spain, employing 11-50 staff.
IMIDomics firmographics
Firmographics- Name
- IMIDomics
- Legal name
- IMIDomics, Inc.
- Website
- https://imidomics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- IMIDomics is a biotechnology company developing first-in-class therapeutics for immune-mediated inflammatory diseases using a proprietary Clinical Discovery Engine built on 17+ years of multi-omics patient data and an ISO-certified biobank of over 17,000 IMID patients, monetizing through licensing and research collaborations with pharmaceutical partners.
- Ownership category
- akta.pro rank
IMIDomics industry classification
Industry- Product category
- Biopharmaceutical Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where IMIDomics is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
IMIDomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Development and Licensing: IMIDomics develops novel therapeutics for IMIDs and partners with pharmaceutical companies for co-development, licensing, and commercialization. Revenue is generated through strategic partnerships, licensing agreements, and potential milestone payments.
- Research Collaborations: Collaborations with pharmaceutical companies for target discovery, biomarker identification, and clinical development support, generating revenue through research funding and development milestones.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
IMIDomics product offering
Product offeringCore offering
IMIDomics discovers and develops first-in-class medicines for immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, lupus, ulcerative colitis, psoriasis, Crohn's disease, and atopic dermatitis. Its proprietary Clinical Discovery Engine combines patient-centric clinical data from over 17,000 IMID patients, multi-omics analyses, and bioinformatics to identify novel drug targets and patient stratification biomarkers. The company partners with pharmaceutical companies (UCB, Bristol Myers Squibb, Evotec) for co-development, licensing, and commercialization of its therapeutic pipeline, including the lead program IMB1001 (anti-CD226 antibody).
Product overview
IMIDomics is a biotechnology company developing the next generation of medicines for immune-mediated inflammatory diseases (IMIDs). The company operates a unified Clinical Discovery Engine platform that combines proprietary patient data, multi-omics analysis, and bioinformatics to discover and develop first-in-class therapeutic targets. The platform integrates an IMID-Biobank with over 17,000 patient samples and clinical data from 130 recruiting centers. IMIDomics' pipeline includes multiple first-in-class programs, with IMB1001 (anti-CD226 antibody) being the most advanced drug candidate that has been out-licensed for further development.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Discovery Engine Proprietary platform combining patient data collection, multi-omics generation (genomics, transcriptomics, epigenetics, proteomics, metabolomics), bioinformatics analysis, and AI/ML for target identification, biomarker discovery, and patient stratification in immune-mediated inflammatory diseases. Offered to pharmaceutical partners for drug discovery and development.
- Precision Discovery Platform AI- and machine learning-enhanced version of IMIDomics' drug discovery platform that leverages comprehensive IMID patient data and biobank resources to identify and develop first-in-class therapeutic targets.
- IMB1001 (Anti-CD226 Antibody) First-in-class antibody program targeting CD226 signaling that modulates both innate and adaptive immunity. Licensed from TNAX Biopharma (as TNAX101A) and being developed for immune-mediated inflammatory diseases by WuXi Biologics (CMC/manufacturing) and Formation Bio (development rights).
- IMID-Biobank ISO-certified biorepository containing over 1 million biological specimens (blood and relevant tissues) from over 17,000 IMID patients and control subjects across eight IMIDs, with cross-sectional and longitudinal data collection. Supports multi-omics research and pharmaceutical partner access.
Quantifiable outcome
- 4 of 5 Ulcerative Colitis patients fail to achieve remission with current treatments
- +2 more outcomes
Companies that use IMIDomics
Customer profileSegments3 records
Ideal customer profiles2 records
IMIDomics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
IMIDomics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Formation BiocoreFormation Bio licensed the first-in-class anti-CD226 autoimmune program from IMIDomics. This represents the first drug licensed by Formation since their $372M raise.
- University of BarcelonaminorLicense and collaboration partnership established in October 2023 to advance treatments for IMIDs. The University of Barcelona contributes academic research expertise to the collaboration.
- WuXi BiologicscoreStrategic agreement announced in October 2023 to advance IMB1001 antibody development for immune-mediated inflammatory diseases. WuXi Biologics provides CMC development and manufacturing capabilities.
- TNAX Biopharma CorporationcoreExclusive worldwide licensing agreement for TNAX101A (IMB1001), a promising drug candidate for IMIDs. TNAX provides access to the compound that became IMB1001.
- Gossamer BiominorStrategic collaboration to advance the development of novel treatments for patients with immune-mediated inflammatory diseases, established in February 2020.
- Vall d'Hebron Institute of Research (VHIR)coreVHIR is a key academic partner providing patient data and sample collection infrastructure. The IMID-Biobank is located at VHIR and samples are stored there. The partnership dates back to the company's origins from the IMID Consortium started by Dr. Sara Marsal.
- DocTIScoreDoCTIS is an EU-funded Horizon 2020 project focused on discovering effective combinatorial therapies for IMIDs using systems approaches. Dr. Sara Marsal serves as coordinator. IMIDomics participates in this broad academic partnership to explore combination therapies.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
IMIDomics competitors and assessment
Company assessmentDirect peers
- Prometheus Biosciences (acquired by Merck): Precision-medicine biotech focused on immune-mediated diseases (IBD, IBD-related) using proprietary patient data and biomarker discovery; very similar discovery-plus-stratification model in the IMID space and the most directly comparable peer.
- Morphic Holding (acquired by Eli Lilly): Clinical-stage biotech developing oral integrin therapeutics for IMIDs including IBD; shares the immunology/inflammation focus and partnership-driven development model with IMIDomics.
- AbCellera Biologics: AI-powered antibody discovery platform partnering with pharma to identify therapeutic candidates; directly comparable as a technology-driven, partnership-monetized antibody/biologic discovery company.
Broad incumbents
- Bristol Myers Squibb: Large pharma with established IMID franchises (Zeposia, Sotyktu, deucravacitinib) and a Series A investor and ongoing collaborator of IMIDomics; competes broadly in the same therapeutic indications.
- AbbVie: Global immunology leader with Humira, Skyrizi, and Rinvoq dominating IMID markets; sets the competitive bar for any new IMID therapeutic including IMIDomics' pipeline.
- UCB: Specialist biopharma with major IMID franchise (Cimzia, evenity, Rystiggo/Zilbrysq); strategic equity investor in and ultimate acquirer of IMIDomics, providing commercial reach for IMIDomics' pipeline.
- Eli Lilly: Major immunology player (Taltz, Olumiant, mirikizumab) actively expanding in IBD and atopic dermatitis; competes for the same indications IMIDomics targets.
Emerging players
- Recursion Pharmaceuticals: AI-driven drug discovery platform using large-scale biological and chemical data to identify novel targets; comparable as a tech-enabled discovery company, though with a broader therapeutic focus than IMIDomics.
- Exscientia: AI-first pharma using precision medicine and computational drug design; shares the AI/ML-enabled discovery and pharma partnership business model with IMIDomics.
- Gossamer Bio: Clinical-stage immunology biotech developing therapeutics for IMIDs (IBD, pulmonary); established strategic collaborator with IMIDomics (2020) addressing overlapping indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
IMIDomics social profiles
Digital presenceIMIDomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
IMIDomics leadership team
Management profileNumber of profiles
Profiles10 records
IMIDomics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IMIDomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IMIDomics
What does IMIDomics do?
IMIDomics discovers and develops first-in-class medicines for immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis, lupus, ulcerative colitis, psoriasis, Crohn's disease, and atopic dermatitis. Its proprietary Clinical Discovery Engine combines patient-centric clinical data from over 17,000 IMID patients, multi-omics analyses, and bioinformatics to identify novel drug targets and patient stratification biomarkers. The company partners with pharmaceutical companies (UCB, Bristol Myers Squibb, Evotec) for co-development, licensing, and commercialization of its therapeutic pipeline, including the lead program IMB1001 (anti-CD226 antibody).
Is IMIDomics a public or private company?
IMIDomics is a private company. It is classified as corporate owned and is currently acquired.
When was IMIDomics founded?
IMIDomics was founded in 2015. It employs 11 to 50 people.
Where is IMIDomics based?
IMIDomics is headquartered in Barcelona, Spain, in the Europe region.
How does IMIDomics make money?
Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are research Collaborations.
Who are IMIDomics's main competitors?
Direct peers on record are Prometheus Biosciences (acquired by Merck), Morphic Holding (acquired by Eli Lilly) and AbCellera Biologics. Broad incumbents are Bristol Myers Squibb, AbbVie, UCB and Eli Lilly. Emerging players are Recursion Pharmaceuticals, Exscientia and Gossamer Bio.
Does IMIDomics have an API?
No public API is recorded for IMIDomics.
What industry is IMIDomics in?
IMIDomics's product category is Biopharmaceutical Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.